It has been reported that Foretinib simultaneously inhibited cancer cells and lymphatic endothelial cells to reduce pancreatic tumor growth in vivo, and suppressed angiogenesis and lymphangiogenesis by blocking VEGFR-2/3 and Tie-2 signaling [21]. The gene discussed is TEK; the disease is pancreatic neoplasm.